Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229344 | 0.85 | PKM (0.43) | GRM1ALDH1A1 | |
| SCHEMBL31116092 | 0.82 | ALDH1A1 (0.33) | GRM1ALDH1A1 | |
| SCHEMBL6229340 | 0.76 | PKM (0.32) | — | |
| SCHEMBL26243859 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL20944070 | 0.76 | FFAR3 (0.32) | — | |
| SCHEMBL18202993 | 0.76 | GRM1 (0.38) | GRM1ALDH1A1 | |
| SCHEMBL17299153 | 0.76 | GRM1 (0.43) | GRM1ALDH1A1 | |
| SCHEMBL6228316 | 0.75 | ALDH1A1 (0.46) | GRM1ALDH1A1 | |
| SCHEMBL6227840 | 0.75 | ALDH1A1 (0.46) | GRM1ALDH1A1 | |
| SCHEMBL4036460 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423075-B1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250042881-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-02-06 | — | — | US | disclosed |
| WO-2025011546-A1 | HUMAN CASEINOLYTIC PROTEASE P AGONISTS AND USES THEREOF | ACELON THERAPEUTICS (CN) | 2025-01-16 | — | — | WO | disclosed |
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-09 | — | — | US | disclosed |
| WO-2024192064-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4423075-A1 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-09-04 | — | — | EP | disclosed |
| EP-4423082-A1 | CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-09-04 | — | — | EP | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3843842-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| WO-2021062199-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042881-A1 | CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR4 | GRM1 222/4885ALDH1A1 1705/4885 |
| US-20250011313-A1 | CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR4 | GRM1 222/4885ALDH1A1 1705/4885 |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | CRBN, VHL, UBQLN2 | GRM1 1979/4885ALDH1A1 4249/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | GRM1 1979/4885ALDH1A1 4249/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | GRM1 1992/4885ALDH1A1 3885/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | GRM1 2488/4885ALDH1A1 1247/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | GRM1 929/4885ALDH1A1 3566/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | GRM1 3359/4885ALDH1A1 1223/4885 |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | GRM1 216/4885ALDH1A1 4554/4885 |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | GRM1 216/4885ALDH1A1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.